News

NEWS

LATEST NEWS

“Good-Risk” Group of Patients With Myeloma Saw Better Outcomes

Monjuvi Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

There are currently limited data to inform an optimal treatment strategy for CRS.

Two Trials Evaluate CAR-T Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma

Doctor Showing Digital Tablet To Patient in ICU

Venous Thromboembolism Events With COVID-19 in an Intensive Care Unit

DEA Warns of Extortion Scam Targeting Healthcare Providers

Deep Vein Thrombosis Detection in Patients With Hemophilia A Undergoing Total Knee Arthroplasty

Genomic Analysis to Determine Patient Survival in Newly Diagnosed Multiple Myeloma

UPCOMING MEETINGS

December 5 – 8, 2020
62ND ASH ANNUAL MEETING AND EXPOSITION
San Diego Convention Center, San Diego, CA

Click here to view the full calendar

DRUG NEWS FROM MPR

FDA Approves New Treatment Option for Multiple Myeloma

Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication

Esperoct Now Available for Treatment of Hemophilia A

Bomedemstat Receives Fast Track Status for Essential Thrombocythemia

Avatrombopag Designated Orphan Drug for Chemo-Induced Thrombocytopenia

Adakveo Approved for Sickle Cell Disease

FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma

Reblozyl Approved for Anemia in Beta Thalassemia

Gene Therapy Gets Orphan Drug Status for Gaucher Disease

Ultomiris Receives Approval for Atypical Hemolytic Uremic Syndrome

Next post in Leukemia

Venetoclax and ibrutinib are therapeutic agents for CLL.

Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients